Financial Performance - The company's net income for Q1 2025 was $27.5 million, or $1.69 per share[8] - Adjusted net income for Q1 2025 was $28.4 million, or $1.74 per share, an increase of $1.2 million or $0.05 per share compared to 2024[8] - The company reaffirms its 2025 earnings guidance to be in the range of $3.01 to $3.17[55] Acquisitions and Growth - The company completed the acquisition of Bangor Natural Gas ("BNG") in January 2025, adding approximately 8,730 customers[8, 36] - The company announced the acquisition of Maine Natural Gas ("MNG") in April 2025 for approximately $86 million, expected to close by the end of the year, adding approximately 6,300 customers[8, 11] - The company announced the acquisition of three water utilities (Aquarion Water (MA & NH) and Abenaki Water (NH)) on May 6, 2025, for an enterprise value of $100 million, including approximately $30 million of debt[8, 18] Rate Base and Capital Investment - The company expects a long-term rate base growth of 6.5% - 8.5%[8] - The company's five-year projected capital investment is approximately $980 million, 46% higher than the prior five years[48] Natural Gas Operations - The company has 86,600 natural gas customers[3, 8, 59, 63, 64, 65, 66, 76, 79, 81] - Adjusted gross margin for gas operations increased by 16.2%, or $9.9 million, reflecting higher rates and customer growth[36, 37]

Q1 2025 Financial Performance - Net sales increased by 10% to $122.8 million[27] - Gross margin decreased from 37.1% to 33.2%[27] - Net income decreased by 12% to $4.8 million, with net income margin decreasing from 4.9% to 3.9%[27] - Adjusted EBITDA decreased by 8% to $21.2 million, with Adjusted EBITDA margin decreasing from 20.5% to 17.2%[27] - Free Cash Flow generation decreased to $0.3 million from $7.4 million in the prior year[27] Segment Performance - Debit and Credit net sales increased from $88.0 million to $96.5 million, while operating income decreased from $22.8 million to $21.7 million[33] - Prepaid Debit net sales increased from $24.2 million to $26.7 million, while operating income increased from $8.0 million to $8.7 million[35] Balance Sheet and Outlook - Net Leverage Ratio was 3.1x as of March 31, 2025[40] - The company affirmed its 2025 full-year outlook, expecting a mid-to-high single-digit increase in net sales and Adjusted EBITDA[11, 46] Strategic Initiatives - CPI acquired Arroweye Solutions, Inc on May 6, 2025, with expected revenues in the mid-$50 million range on an annualized basis[19, 21] - The company is focused on innovation and diversification to expand addressable markets[15]

Overall Performance - Uber's Gross Bookings ARR reached $82 billion, a 18% year-over-year increase in Q1 2025[16] - Adjusted EBITDA ARR was $3.1 billion, up 45% year-over-year in Q1 2025[16] - Q1 2025 Adjusted EBITDA was $1.868 billion, a 35% year-over-year increase[47] - Uber's Q1 2025 revenue increased by 17% year-over-year to $11.533 billion[44] - Net income attributable to Uber Technologies, Inc was $1.776 billion[70] Segment Highlights - Delivery Gross Bookings grew 18% year-over-year[59] - Delivery Adjusted EBITDA was $763 million[59] - Mobility Gross Bookings grew 20% year-over-year[56] - Mobility Adjusted EBITDA was $1.753 billion[52] - Freight revenue was $1.260 billion[64]

Financial Performance - RXO reported Q1 2025 adjusted EBITDA of $22 million[13] compared to $15 million in Q1 2024[12] - Q1 2025 revenue reached $1433 million, a 56.9% increase from $913 million in Q1 2024[12] - RXO reported Q1 2025 adjusted diluted EPS of $(003)[31] which is the same as Q1 2024[30] - The company's gross margin was 160% in Q1 2025, down from 174% in Q1 2024[12] Synergy and Integration - RXO is raising its synergy target to >$70 million, including $60 million in operating expense synergies and $10 million in capital expenditure synergies[29] - The migration of Coyote carrier and coverage operations to the RXO Connect platform was completed on May 1[23, 27] - Technology integration is expected to be substantially complete by the end of Q3[23] Volume and Market Trends - Truckload revenue per load was up 4% year-over-year[42] - LTL volume increased by 26% year-over-year, representing 25% of the total volume[19] - Last Mile stop growth accelerated to 24% year-over-year[19] Q2 2025 Outlook - RXO anticipates adjusted EBITDA to be between $30 million and $40 million[54] - The company expects brokerage volume to be down low-single-digit % year-over-year[54] - Brokerage gross margin is projected to be between 13% and 15%[54]

Q1 2025 Earnings Overview - SuRo Capital's NAV per share was $666 as of March 31, 2025[8] - The company's net assets were approximately $1568 million at quarter-end[8] - A new portfolio company investment was made in Plaid Inc for $50 million[7] - An additional $50 million debt refinance occurred in Q1[8] - $353 million in 600% Notes due 2026 were repurchased to date[11] - $350 million in 650% Convertible Notes due 2029 were issued to date[11] Portfolio Company Activity - CoreWeave, Inc successfully executed an IPO on March 28th[8] According to Reuters, CoreWeave raised over $15 billion from the listing at a valuation of approximately $230 billion[32, 38] - OpenAI announced a $400 billion financing round at a $3000 billion post-money valuation[8, 32, 47] Portfolio Composition - The top 5 positions accounted for 46% of the investment portfolio at fair value, based on a total investment portfolio fair value of $2136 million at March 31, 2025[29, 30]

Financial Performance - Q1 2025 revenue reached $17.6 million[11], compared to $12.9 million in Q1 2024[11] - Gross margin in Q1 2025 was 51%[11], a decrease from 56% in Q1 2024[11] - Net loss for Q1 2025 was $28.7 million[30], compared to a net loss of $12.4 million in Q1 2024[30] - Adjusted EBITDA for Q1 2025 was ($15.5) million[30], compared to ($7.8) million in Q1 2024[30] Key Metrics - New patient starts in Q1 2025 were 3,853[11], compared to 2,597 in Q1 2024[11] - 51% of new patient starts in Q1 2025 were reimbursed through pharmacy[11] - 71% of new patient starts in Q1 2025 came from multiple daily injections[30] 2025 Guidance - Full year 2025 total revenue is projected to be between $82 million and $87 million[18] - The company anticipates new patient starts through pharmacy to be 22-25% for the full year 2025[18] - Gross margin is expected to be 50-53% for the full year 2025[18] Strategic Highlights - The company raised approximately $206 million in net proceeds from its Initial Public Offering (IPO) in January 2025[15]

Company Overview - Varonis' Annual Recurring Revenue (ARR) reached $664.3 million, representing a 19% year-over-year growth[8,44] - SaaS ARR constitutes approximately 61% of the total ARR[8,44] - The company's Year-To-Date (YTD) Operating Cash Flow is $68.0 million, and YTD Free Cash Flow is $65.3 million[8,44] Market Trends - The amount of data created globally is projected to grow at a compound annual growth rate of 24% by 2028, with unstructured data accounting for over 90% of the total data generated[18] - It is expected that 90% of organizations will adopt a hybrid cloud approach by 2027, and over 80% of enterprises are expected to use Generative AI by 2026[18] - The global average cost of a data breach in 2024 was $4.9 million, with 40% of breaches involving data stores across multiple environments[18] Financial Performance & Guidance - The company anticipates Annual Recurring Revenues (ARR) between $742.0 million and $750.0 million for the full year 2025, indicating a year-over-year growth of 16% to 17%[53] - The company projects total revenues between $610.0 million and $625.0 million for the full year 2025, representing a year-over-year growth of 11% to 13%[53] - The company expects Free Cash Flow between $120.0 million and $125.0 million for the full year 2025[53]

This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934. Forward-looking statements generally relate to opinions, beliefs, and projections of expected future financial and operating performance, business trends, liquidity, and market conditions, among other things. These forward-looking statements are based upon current expectations and assumptions and often can be identified by words such as "expect," "strive," "looking ahead," "outlook, ...

Financial Performance & Guidance - Sarepta revised its FY 2025 total product revenue guidance to $23 billion - $26 billion[13] - Q1 2025 total revenues reached $745 million, an 80% increase compared to $413 million in Q1 2024[49] - Q1 2025 total product revenue was $612 million, a 70% increase from $359 million in Q1 2024[18, 49] - The company reported a GAAP operating loss of $300 million in Q1 2025, compared to an income of $35 million in Q1 2024[44, 49] - Non-GAAP operating loss for Q1 2025 was $250 million, compared to an income of $84 million in Q1 2024[44, 49] ELEVIDYS Performance - ELEVIDYS sales grew 180% year-over-year, but fell short of expectations[13] - Over 800 patients have been treated with ELEVIDYS in commercial settings and clinical studies[13, 25] R&D and Pipeline - The company is on track for BLA submission for SRP-9003 for LGMD2E/R4 in the second half of 2025[13] - Enrollment and dosing are completed in Study SRP-9004-102 for LGMD2D/R3[13] Arrowhead Collaboration - The company closed a global licensing and collaboration agreement with ARWR for multiple targets[12] - Q1 2025 GAAP and Non-GAAP R&D expenses include Arrowhead collaboration transaction costs of $584 million[49]

Q1 2025 Earnings Release Supplement Refer to earnings release dated May 6, 2025 for further information ^ - dark blue-teal #00B5E2 ^ - light raspberry #981239 ^ - dark raspberry #981239 ^ - light blue-teal #59CBE8 ^ - cool gray 1 #E6E8E7 ^ - maroon #3D1628 Q1 Safe Harbor Provision 2025 ^ This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about Corpay's (formerly known as Fleetcor Technologies ...